Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R2CI
|
|||
| Former ID |
DPR000052
|
|||
| Drug Name |
GI-264879A
|
|||
| Synonyms |
gi264879a
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Preclinical | [1] | |
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C41H44F3N5O5
|
|||
| Canonical SMILES |
COCC(CC1=CC=CC=C1)NC(=O)C(CCCN=C(N)N)NC(=O)CC(C2=CC=CC3=CC=CC=C32)C4=CC=CC5=CC=CC=C54.C(=O)(C(F)(F)F)O
|
|||
| InChI |
1S/C39H43N5O3.C2HF3O2/c1-47-26-30(24-27-12-3-2-4-13-27)43-38(46)36(22-11-23-42-39(40)41)44-37(45)25-35(33-20-9-16-28-14-5-7-18-31(28)33)34-21-10-17-29-15-6-8-19-32(29)34;3-2(4,5)1(6)7/h2-10,12-21,30,35-36H,11,22-26H2,1H3,(H,43,46)(H,44,45)(H4,40,41,42);(H,6,7)/t30-,36+;/m0./s1
|
|||
| InChIKey |
NZGALICACGXBQM-HOBHVFGFSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuropeptide Y receptor type 1 (NPY1R) | Target Info | Antagonist | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.